• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

    2/14/23 4:06:28 PM ET
    $PEAR
    Computer Software: Prepackaged Software
    Technology
    Get the next $PEAR alert in real time by email
    SC 13G/A 1 d441492dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Pear Therapeutics, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    704723105

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 704723105    Schedule 13G    Page 1 of 10

     

      1    

      Names of Reporting Persons

     

      SB Global Advisers Limited

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      England and Wales

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      12,100,078

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      12,100,078

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,100,078

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      8.6%

    12  

      Type of Reporting Person

     

      CO


    CUSIP No. 704723105    Schedule 13G    Page 2 of 10

     

      1    

      Names of Reporting Persons

     

      SoftBank Vision Fund II-2 L.P.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Jersey

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      12,100,078

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      12,100,078

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,100,078

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      8.6%

    12  

      Type of Reporting Person

     

      PN


    CUSIP No. 704723105    Schedule 13G    Page 3 of 10

     

      1    

      Names of Reporting Persons

     

      SVF II Aggregator (Jersey) L.P.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Jersey

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      12,100,078

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      12,100,078

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,100,078

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      8.6%

    12  

      Type of Reporting Person

     

      PN


    CUSIP No. 704723105    Schedule 13G    Page 4 of 10

     

      1    

      Names of Reporting Persons

     

      SVF II Holdings (DE) LLC

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      12,100,078

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      12,100,078

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,100,078

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      8.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)


    CUSIP No. 704723105    Schedule 13G    Page 5 of 10

     

      1    

      Names of Reporting Persons

     

      SVF II Cobbler (DE) LLC

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      12,100,078

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      12,100,078

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,100,078

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      8.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)


    CUSIP No. 704723105    Schedule 13G    Page 6 of 10

     

    ITEM 1.

    (a) Name of Issuer:

    Pear Therapeutics, Inc. (the “Issuer”).

    (b) Address of Issuer’s Principal Executive Offices:

    200 State Street, 13th Floor, Boston, MA 02109.

     

    ITEM 2.

    (a) Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    SB Global Advisers Limited (“SBGA”)

    SoftBank Vision Fund II-2 L.P.

    SVF II Aggregator (Jersey) L.P.

    SVF II Holdings (DE) LLC

    SVF II Cobbler (DE) LLC

    (b) Address or Principal Business Office:

    The principal business address for SBGA is 69 Grosvenor Street, London W1K 3JP, United Kingdom. The principal business address for each of SoftBank Vision Fund II-2 L.P. and SVF II Aggregator (Jersey) L.P. is Crestbridge Limited, 47 Esplanade, St. Helier, Jersey, JE1 0BD. The principal business address for each of SVF II Holdings (DE) LLC and SVF II Cobbler (DE) LLC is 251 Little Falls Drive, Wilmington, DE 19808.

    (c) Citizenship of each Reporting Person is:

    SBGA is organized under the laws of England and Wales. Each of SoftBank Vision Fund II-2 L.P. and SVF II Aggregator (Jersey) L.P. is organized under the laws of Jersey. Each of SVF II Holdings (DE) LLC and SVF II Cobbler (DE) LLC is organized under the laws of the State of Delaware.

    (d) Title of Class of Securities:

    Class A common stock, par value $0.0001 per share (“Class A Common Stock”).

    (e) CUSIP Number:

    704723105


    CUSIP No. 704723105    Schedule 13G    Page 7 of 10

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of shares of Class A Common Stock of the Issuer based upon 140,028,325 shares of Class A Common Stock outstanding as of December 1, 2022, as reported in the Issuer’s prospectus filed with the SEC on January 4, 2023.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole
    power
    to vote
    or to
    direct
    the
    vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    SB Global Advisers Limited

         12,100,078        8.6 %      0        12,100,078        0        12,100,078  

    SoftBank Vision Fund II-2 L.P.

         12,100,078        8.6 %      0        12,100,078        0        12,100,078  

    SVF II Aggregator (Jersey) L.P.

         12,100,078        8.6 %      0        12,100,078        0        12,100,078  

    SVF II Holdings (DE) LLC

         12,100,078        8.6 %      0        12,100,078        0        12,100,078  

    SVF II Cobbler (DE) LLC

         12,100,078        8.6 %      0        12,100,078        0        12,100,078  

    SVF II Cobbler (DE) LLC is the record holder of 12,100,078 shares of Class A Common Stock. SoftBank Vision Fund II-2 L.P. is the sole limited partner of SVF II Aggregator (Jersey) L.P., which is the sole member of SVF II Holdings (DE) LLC, which is the sole member of SVF II Cobbler (DE) LLC.

    SBGA has been appointed as manager and is responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund II-2 L.P.’s investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.


    CUSIP No. 704723105    Schedule 13G    Page 8 of 10

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 704723105    Schedule 13G    Page 9 of 10

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2023

     

    SB Global Advisers Limited
    By:   /s/ Alex Clavel
    Name:   Alex Clavel
    Title:   Director
    SoftBank Vision Fund II-2 L.P.
    By: SB Global Advisers Limited, its Manager
    By:   /s/ Alex Clavel
    Name:   Alex Clavel
    Title:   Director
    SVF II Aggregator (Jersey) L.P.
    By: SB Global Advisers Limited, its Manager
    By:   /s/ Alex Clavel
    Name:   Alex Clavel
    Title:   Director
    SVF II Holdings (DE) LLC
    By:   /s/ Jonathan Duckles
    Name:   Jonathan Duckles
    Title:   Director
    SVF II Cobbler (DE) LLC
    By:   /s/ Jonathan Duckles
    Name:   Jonathan Duckles
    Title:   Director


    CUSIP No. 704723105    Schedule 13G    Page 10 of 10

     

    LIST OF EXHIBITS

     

    Exhibit No.   

    Description

    99    Joint Filing Agreement.

     

    Get the next $PEAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEAR

    DatePrice TargetRatingAnalyst
    1/26/2022$5.00Neutral
    B of A Securities
    1/20/2022$11.00Outperform
    Credit Suisse
    1/3/2022$12.00Buy
    BTIG Research
    12/29/2021$13.00Buy
    Citigroup
    12/22/2021$16.00Buy
    Chardan Capital
    12/16/2021Outperform
    Cowen & Co.
    More analyst ratings

    $PEAR
    Financials

    Live finance-specific insights

    See more
    • Pear Therapeutics Reports Third Quarter 2022 Results

      Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

      11/14/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

      Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

      10/31/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports Second Quarter 2022 Results

      20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

      8/11/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

      Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

      4/7/23 11:30:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

      SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

      3/23/23 10:19:01 AM ET
      $CDTX
      $ELVN
      $IMPL
      $PEAR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Prepackaged Software

    $PEAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B of A Securities initiated coverage on Pear Therapeutics with a new price target

      B of A Securities initiated coverage of Pear Therapeutics with a rating of Neutral and set a new price target of $5.00

      1/26/22 7:01:40 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Credit Suisse initiated coverage on Pear Therapeutics with a new price target

      Credit Suisse initiated coverage of Pear Therapeutics with a rating of Outperform and set a new price target of $11.00

      1/20/22 7:36:22 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • BTIG Research initiated coverage on Pear Therapeutics with a new price target

      BTIG Research initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $12.00

      1/3/22 7:33:46 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Pear Therapeutics Inc.

      25-NSE - Pear Therapeutics, Inc. (0001835567) (Subject)

      5/2/23 1:36:49 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/10/23 4:36:29 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/7/23 11:32:19 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/28/23 4:07:09 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/12/23 4:33:35 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/23 4:06:28 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by 5am Partners Iv, Llc

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      4/12/23 4:51:37 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Snow Ellen

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:54 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Brenner Erin K.

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:18 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Jorge Gomez Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

      4/11/22 9:00:00 AM ET
      $CAH
      $MRNA
      $PEAR
      $XRAY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Prepackaged Software